Regenerative therapies based mostly on mesenchymal stromal cells (MSCs) supply hope for sufferers affected by osteoarthritis, power joint degeneration situations, and cartilage accidents. Rather than taking medicines that merely masks their ache and signs, MSCs can differentiate into new cartilage cells to immediately exchange broken tissue, whereas additionally releasing paracrine elements to stimulate the physique’s personal restore mechanisms.

While MSC-based regenerative therapies do maintain nice promise for sufferers, MSCs are very troublesome to fabricate within the laboratory, which has restricted their usefulness.

Now, researchers from the Singapore-MIT Alliance for Research and Technology (SMART) have developed a fast, non-destructive option to monitor MSCs in real-time. This strategy may give scientists an early indication of whether or not their cells will be capable of type high-quality cartilage tissue, permitting for quicker decision-making and higher manufacturing timelines.

The challenges of MSC-based therapies

One of the most important limiting elements for MSC-based therapies is the inherent unpredictability of MSCs’ chondrogenic potential—their capability to develop and type cartilage tissue—throughout the in vitro manufacturing course of.

“MSCs are difficult to grow because they are naturally very diverse. Cells from different donors can behave differently depending on age, health, and genetics. Even within the same sample, individual cells are not identical,” research creator Prof. Jongyoon Han, co-lead principal investigator on the Critical Analytics for Manufacturing Personalised-Medicine (CAMP) and a professor of organic engineering at MIT, instructed Technology Networks.

“Even within carefully controlled and consistent lab conditions, MSC growth still shows surprising variability. When we grow these cells in the lab, some cells grow faster, some change in size, and others lose their ability to develop into the desired tissue,” Han mentioned.

While there are checks that scientists can use to judge their MSCs’ chondrogenic potential, these checks can require as much as 21 days of cell progress for a pattern and can render them too broken for additional use.

“Researchers have tried many ways to assess cell quality, such as examining cell shape, movement, or gene and protein expression. However, these methods are often time-consuming or damaging to the cells,” Han mentioned.

“As a result, there is a high demand for reliable, non-invasive ways to predict how well MSCs will perform before they are used. In our research, we’ve developed a rapid, non-destructive method to predict the cell’s ability to grow cartilage tissue for cartilage repair.”

Iron flux and MSC progress

The group’s technique hinges on measuring iron flux in MSCs. At regular ranges, iron can help important capabilities for these cells, corresponding to cell progress, DNA synthesis, and the formation of the collagen wanted to construct cartilage. However, the uptake of an excessive amount of iron can result in accumulation and generate dangerous oxidative stress, inflicting cell harm.

“[Iron levels] continuously change in response to the culture environment, such as media composition and handling conditions. These subtle differences can drive significant variability between cell batches,” Han defined.

“That’s why we focus on iron flux, which captures how iron changes over time rather than just measuring a single snapshot. In our work, we found that this dynamic iron profile closely correlates with the cells’ ability to form cartilage, making it a powerful indicator of a cell’s quality for cartilage repair.”

The measurement methodology begins by including ascorbic acid (AA) to spent media samples; the addition of AA helps to control iron homeostasis by limiting iron flux. Then, utilizing a micromagnetic resonance relaxometry (µMRR) machine, the group can measure delicate adjustments in iron focus within the MSCs.

“µMRR is a technique that measures how water behaves in a magnetic field. Because most biological samples are largely made up of water, this provides a very sensitive way to probe what’s happening inside them,” Han defined.

“In a pure water system, the sign from water molecules is steady and predictable. However, when paramagnetic ions, corresponding to iron, are current, they act like tiny magnets and regionally disturb the magnetic subject. This causes the water sign to fade extra rapidly.

“μMRR works by measuring how fast this signal decays—a parameter known as the T₂ relaxation time. The more iron in the sample, the faster this decay occurs. By calibrating this relationship, we can accurately determine the iron concentration,” Han mentioned.

How can this analysis allow higher regenerative remedy manufacturing?

Unlike earlier testing choices, this new methodology is non-destructive and gives a fast answer to measuring MSCs’ chondrogenic capability.

“Importantly, using μMRR, we can monitor iron flux from a small amount of spent culture media, with high sensitivity and without damaging the cells,” Han mentioned. “This allows us to shift from simply ‘growing more cells’ to ‘growing high-quality cells.’ By monitoring iron flux in real time, we can assess cell quality during production, identify issues early, and adjust conditions as needed, providing this insight up to 21 days earlier than standard existing tests.”

“Ultimately, this approach can make cell therapy manufacturing more consistent, efficient, and reliable, bringing us closer to delivering safer and more effective treatments to patients,” Han added.

The researchers plan to construct on these findings by increasing their strategy past MSCs, to see whether or not different superior cell therapies, corresponding to iPSC-derived merchandise and CAR T cells, may also profit from this evaluation.

iPSC remedy

Induced pluripotent stem cell (iPSC) remedy makes use of reprogrammed adult stem cells to create patient-specific cells. iPSC remedy has functions in creating specialised cells for repairing broken neurons in Parkinson’s illness, retinal cells in macular degeneration, and different degenerative illnesses.

CAR T-cell remedy

Chimeric antigen receptor (CAR) T-cell therapy is a sort of personalised immunotherapy that modifies a affected person’s personal T cells to acknowledge and destroy most cancers cells. It is used primarily within the therapy of blood cancers.

“Because iron is a fundamental regulator of cellular metabolism and function, iron flux has the potential to serve as a universal indicator of cell quality across multiple therapeutic platforms,” Han mentioned.

“Another important direction is to translate this technology into real-world manufacturing. By enabling real-time, non-destructive, and high-throughput monitoring, this approach could allow manufacturers to detect quality deviations early, adjust culture conditions rapidly, and significantly improve consistency and efficiency at scale.”

Beyond cell remedy manufacturing, the SMART analysis group can also be eager to judge the usefulness of this method for different functions in iron biology.

“For the first time, we can track iron dynamics in a time-resolved and sensitive manner, providing insight into how iron regulates cell growth, stress responses, and differentiation, which has been difficult to capture with existing methods,” Han concluded.

Reference: Yang Y, Kang M, Chen M, Cui L, Yang Z, Han J. Cellular iron flux measurement by micromagnetic resonance relaxometry as a crucial high quality attribute of mesenchymal stromal cells. Stem Cells Transl Med. 2026;15(2):szaf080. doi: 10.1093/stcltm/szaf080

About the interviewee:

Jongyoon Han, PhD, is a professor within the Department of Electrical Engineering and Computer Science and Biological Engineering on the Massachusetts Institute of Technology. He obtained a BS (1992) and an MS (1994) diploma in physics from Seoul National University, Seoul, Korea, and a PhD in utilized physics from Cornell University in 2001. He obtained the NSF CAREER (2003) and the Analytical Chemistry Young Innovator Award (ACS, 2009). His present analysis is concentrated on engineering revolutionary microfluidic options to varied biomanufacturing challenges, together with upstream and downstream bioprocessing of CHO and HEK 293 cells, assays for crucial high quality attributes (CQAs) for cell therapies, and methodologies for security assurance. He is at the moment the lead Principal Investigator (PI) for MIT’s participation in NIIMBL (The National Institute for Innovation in Manufacturing Biopharmaceuticals). He can also be a co-lead PI for the Critical Analytics for Manufacturing Personalised-Medicine (CAMP) interdisciplinary analysis group (IRG) at Singapore-MIT Alliance for Research and Technology (SMART), MIT’s analysis enterprise in Singapore, the place novel CQAs for cell therapies are being developed.



Sources

Leave a Reply

Your email address will not be published. Required fields are marked *